XENE

56.85

0.28% 0.16

Dopo l'orario di chiusura: 56.85

Xenon Pharmaceuticals Inc (XENE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$56.69

Aprire:

$56

Volume 24 ore:

897.20K

Relative Volume:

0.65

Capitalizzazione di mercato:

$5.43B

Reddito:

$7.50M

Utile/perdita netta:

$-345.91M

Rapporto P/E:

-13.04

EPS:

-4.3602

Flusso di cassa netto:

$-280.51M

1 W Prestazione:

+2.38%

1M Prestazione:

+33.61%

6M Prestazione:

+45.03%

1 anno Prestazione:

+80.71%

Intervallo 1D:

$55.86

$57.44

Intervallo di 1 settimana:

$53.62

$59.44

Portata 52W:

$26.74

$63.95

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Nome

Xenon Pharmaceuticals Inc

Settore

Healthcare (1118)

Industria

Biotechnology (624)

Telefono

(604) 484-3300

Indirizzo

200 - 3650 GILMORE WAY, BURNABY

Dipendente

370

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

XENE's Discussions on Twitter

Compare XENE vs VRTX, REGN, ARGX, ALNY, INSM

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
XENE Xenon Pharmaceuticals Inc	56.85	5.43B	7.50M	-345.91M	-280.51M	-4.3602
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2025-09-03	Ripresa	Wells Fargo	Overweight
2025-05-07	Iniziato	Chardan Capital Markets	Buy
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-10-10	Ripresa	Raymond James	Outperform
2024-10-01	Iniziato	H.C. Wainwright	Buy
2024-01-04	Iniziato	Citigroup	Buy
2023-12-08	Iniziato	Robert W. Baird	Outperform
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-04-25	Iniziato	Cantor Fitzgerald	Overweight
2022-12-14	Iniziato	Goldman	Buy
2022-12-12	Iniziato	Cowen	Outperform
2022-11-28	Iniziato	Wells Fargo	Overweight
2022-10-19	Iniziato	Raymond James	Outperform
2022-08-29	Iniziato	BofA Securities	Buy
2022-07-21	Iniziato	JP Morgan	Overweight
2021-10-28	Iniziato	RBC Capital Mkts	Outperform
2020-10-02	Iniziato	SVB Leerink	Outperform
2020-07-21	Iniziato	Needham	Buy
2020-06-01	Ripresa	Jefferies	Buy
2020-03-25	Iniziato	Wedbush	Outperform
2020-01-08	Iniziato	William Blair	Outperform
2019-09-20	Iniziato	Guggenheim	Buy
2018-08-08	Reiterato	Stifel	Buy
2017-03-13	Iniziato	Jefferies	Buy
2016-10-21	Iniziato	Stifel	Buy
2016-09-26	Iniziato	Guggenheim	Buy
2016-04-14	Reiterato	Jefferies	Buy
2015-10-30	Ripresa	Jefferies	Buy
2014-12-02	Iniziato	Canaccord Genuity	Buy

Mostra tutto

Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie

Apr 05, 2026

XENE SEC FilingsXenon Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 05, 2026

Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat

Apr 05, 2026

Apr 04, 2026

Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN

Apr 04, 2026

XENE Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai

Apr 04, 2026

XENE PE Ratio & Valuation, Is XENE Overvalued - intellectia.ai

Apr 04, 2026

Apr 02, 2026

Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal

Apr 02, 2026

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat

Apr 02, 2026

Mar 31, 2026

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com

Mar 31, 2026

Mar 30, 2026

Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN

Mar 30, 2026

How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors - Sahm

Mar 30, 2026

Mar 29, 2026

Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat

Mar 29, 2026

Mar 28, 2026

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - marketbeat.com

Mar 28, 2026

Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise - Sahm

Mar 28, 2026

Mar 27, 2026

Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool

Mar 27, 2026

Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01 - msn.com

Mar 27, 2026

Mar 25, 2026

Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN

Mar 25, 2026

Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN

Mar 21, 2026

Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS

Mar 21, 2026

Mar 20, 2026

JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com

Mar 20, 2026

Mar 19, 2026

Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget

Mar 19, 2026

Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail

Mar 19, 2026

Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat

Mar 19, 2026

Xenon Pharmaceuticals (XENE) Is Down 6.7% After Major Equity Raise Post X-TOLE2 DataHas The Bull Case Changed? - Sahm

Mar 19, 2026

Mar 18, 2026

Xenon Pharmaceuticals (XENE) Is Down 6.7% After $650 Million Follow-On Offering And Phase 3 Epilepsy Win - Yahoo Finance

Mar 18, 2026

Mar 17, 2026

Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 X TOLE2 Azetukalner Results - simplywall.st

Mar 17, 2026

XENE stock up as Azetukalner meets goal in focal onset seizures study - MSN

Mar 17, 2026

XENE Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 17, 2026

Jain Global LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat

Mar 17, 2026